Bernard MALISSEN, Chairman

Bernard MALISSEN is an immunologist, currently Research Director at CNRS (Marseille/France) and formerly Director of the INSERM-CNRS Marseille Luminy Immunology Centre (CIML). He is one of the pioneers in the field of molecular immunology in Europe and has devoted most of his working life to antigen recognition and activation of T cells, as well as the genetics of the T receptor.

Philip GREENBERG

Philip GREENBERG is a professor of medicine and immunology at the University of Washington and heads the immunology department at the Fred Hutchinson Cancer Research Center in Seattle. Philip Greenberg's laboratory focuses on studying anti-tumor T cell response and developing new cell and molecular approaches for immune intervention in oncology. He is one of the pioneers in adoptive cell immunotherapy.

Ron LEVY

Ron LEVY is a professor of medicine and Chief Division of Oncology at Stanford School of Medicine. His research is focused on the study of lymphomas and tumors of the immune system. He helped to develop and test the first antibody against cancer to be approved by the US Food and Drug Administration (FDA) for the treatment of lymphoma.

He was elected to the National Academy of Sciences in 2008.

David RAULET

David RAULET is a specialist in cell and molecular immunology. He has made significant contributions to the advancement of knowledge on γδ T lymphocytes and NK cells. His most recent work is related to stimulator and inhibitor receptors activated by NK cells to detect tumor cells, and the molecules corresponding to these receptors. Mr Raulet was the head of the Immunology Department at the University of California at Berkeley and teaches immunology in the Department of Cell and Molecular Biology.

François ROMAGNÉ

François ROMAGNÉ is a co-founder of Innate Pharma, Chief Scientific Officer and was a member of the Executive Board from the Company’s inception until the end of 2013. He was decisive in building the Company and its portfolio of first-in-class antibodies.
He is now the Director of MImAbs, the new immuno-technology platform at Aix-Marseille University, which Innate Pharma co-founded.